The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive ...

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors ... With strong progression-free survival benefits demonstrated in the ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine ... paired triplet misses survival mark in kidney cancer, Exelixis shifts ...

The approval was based on progression-free survival (PFS) and overall response rates (ORRs ... of Dana-Farber Cancer Institute, Boston, stated in a press release from Exelixis.

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

While there have been massive strides forward in treating cancer in the last decades – with a doubling in survival rates in the last 50 years – a failure to identify patients with earlier ...

Cabozantinib significantly improved progression free survival in patients with pNET ... well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic ...